The Aryl Hydrocarbon Receptor Repressor is a Putative Tumor Suppressor Gene in Multiple Human Cancers

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2008 Jan 4

PMID 18172554

Citations 110

Authors

Enrique Zudaire

Natalia Cuesta

Vundavalli Murty

Karen Woodson

Lisa Adams

Nieves Gonzalez

Alfredo Martinez

Gopeshwar Narayan

Ilan Kirsch

Wilbur Franklin

Fred Hirsch

Michael Birrer

Frank Cuttitta

Affiliations

Soon will be listed here.

Abstract

The aryl hydrocarbon receptor repressor (AHRR) is a bHLH/Per-ARNT-Sim transcription factor located in a region of chromosome 5 (5p15.3) that has been proposed to contain one or more tumor suppressor genes. We report here consistent downregulation of AHRR mRNA in human malignant tissue from different anatomical origins, including colon, breast, lung, stomach, cervix, and ovary, and demonstrate DNA hypermethylation as the regulatory mechanism of AHRR gene silencing. Knockdown of AHRR gene expression in a human lung cancer cell line using siRNA significantly enhanced in vitro anchorage-dependent and -independent cell growth as well as cell growth after transplantation into immunocompromised mice. In addition, knockdown of AHRR in non-clonable normal human mammary epithelial cells enabled them to grow in an anchorage-independent manner. Further, downregulation of AHRR expression in the human lung cancer cell line conferred resistance to apoptotic signals and enhanced motility and invasion in vitro and angiogenic potential in vivo. Ectopic expression of AHRR in tumor cells resulted in diminished anchorage-dependent and -independent cell growth and reduced angiogenic potential. These results therefore demonstrate that AHRR is a putative new tumor suppressor gene in multiple types of human cancers.

Citing Articles

Unveiling the Immune effects of AHR in tumors: a decade of insights from bibliometric analysis (2010-2023).

Xie A, Wang T, Shi W, He F, Sun X, Li P Discov Oncol. 2024; 15(1):616.

PMID: 39495340 PMC: 11535112. DOI: 10.1007/s12672-024-01480-5.

A Narrative Review: Immunometabolic Interactions of Host-Gut Microbiota and Botanical Active Ingredients in Gastrointestinal Cancers.

Li S, Feng W, Wu J, Cui H, Wang Y, Liang T Int J Mol Sci. 2024; 25(16).

PMID: 39201782 PMC: 11354385. DOI: 10.3390/ijms25169096.

High Expression of AhR and Environmental Pollution as AhR-Linked Ligands Impact on Oncogenic Signaling Pathways in Western Patients with Gastric Cancer-A Pilot Study.

Perrot-Applanat M, Pimpie C, Vacher S, Pocard M, Baud V Biomedicines. 2024; 12(8).

PMID: 39200369 PMC: 11351739. DOI: 10.3390/biomedicines12081905.

The AHR repressor limits expression of antimicrobial genes but not AHR-dependent genes in intestinal eosinophils.

Weighardt H, Shapiro M, Mayer M, Forster I, Stockinger B, Diny N J Leukoc Biol. 2024; 116(2):369-378.

PMID: 38701199 PMC: 11271977. DOI: 10.1093/jleuko/qiae105.

AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.

Monje N, Dragomir M, Sinn B, Hoffmann I, Makhmut A, Simon T Br J Cancer. 2024; 130(8):1249-1260.

PMID: 38361045 PMC: 11014847. DOI: 10.1038/s41416-023-02550-1.

References

Donehower L, Harvey M, Slagle B, McArthur M, Montgomery Jr C, Butel J . Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992; 356(6366):215-21. DOI: 10.1038/356215a0. View

Moennikes O, Loeppen S, Buchmann A, Andersson P, Ittrich C, Poellinger L . A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res. 2004; 64(14):4707-10. DOI: 10.1158/0008-5472.CAN-03-0875. View

Elferink C . Aryl hydrocarbon receptor-mediated cell cycle control. Prog Cell Cycle Res. 2003; 5:261-7. View

Jones P, Laird P . Cancer epigenetics comes of age. Nat Genet. 1999; 21(2):163-7. DOI: 10.1038/5947. View

Quandt K, Frech K, Karas H, Wingender E, Werner T . MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 1995; 23(23):4878-84. PMC: 307478. DOI: 10.1093/nar/23.23.4878. View

Mulero-Navarro S, Pozo-Guisado E, Perez-Mancera P, Alvarez-Barrientos A, Catalina-Fernandez I, Hernandez-Nieto E . Immortalized mouse mammary fibroblasts lacking dioxin receptor have impaired tumorigenicity in a subcutaneous mouse xenograft model. J Biol Chem. 2005; 280(31):28731-41. DOI: 10.1074/jbc.M504538200. View

SOULE H, Maloney T, WOLMAN S, PETERSON Jr W, Brenz R, McGrath C . Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50(18):6075-86. View

Hendricks D, Taylor R, Reed M, Birrer M . FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 1997; 57(11):2112-5. View

Downward J . RNA interference libraries prove their worth in hunt for tumor suppressor genes. Cell. 2005; 121(6):813-5. DOI: 10.1016/j.cell.2005.06.002. View

10.

Andersson P, McGuire J, Rubio C, Gradin K, Whitelaw M, Pettersson S . A constitutively active dioxin/aryl hydrocarbon receptor induces stomach tumors. Proc Natl Acad Sci U S A. 2002; 99(15):9990-5. PMC: 126612. DOI: 10.1073/pnas.152706299. View

11.

Hsia D, Mitra S, Hauck C, Streblow D, Nelson J, Ilic D . Differential regulation of cell motility and invasion by FAK. J Cell Biol. 2003; 160(5):753-67. PMC: 2173366. DOI: 10.1083/jcb.200212114. View

12.

Bohm M, Wieland I . Loss of heterozygosity analysis on chromosome 5p defines 5p13-12 as the critical region involved in tumor progression of bladder carcinomas. Int J Cancer. 2001; 89(2):194-7. View

13.

Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C . Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem. 1994; 269(43):26988-95. View

14.

Hoffman E, Reyes H, Chu F, Sander F, Conley L, Brooks B . Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 1991; 252(5008):954-8. DOI: 10.1126/science.1852076. View

15.

Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang F, Villella J . Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer. 2003; 2:24. PMC: 156646. DOI: 10.1186/1476-4598-2-24. View

16.

Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Buchler M . Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene. 2002; 21(39):6059-70. DOI: 10.1038/sj.onc.1205633. View

17.

Burbach K, Poland A, Bradfield C . Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci U S A. 1992; 89(17):8185-9. PMC: 49882. DOI: 10.1073/pnas.89.17.8185. View

18.

Mitra A, Murty V, Singh V, Li R, Pratap M, Sodhani P . Genetic alterations at 5p15: a potential marker for progression of precancerous lesions of the uterine cervix. J Natl Cancer Inst. 1995; 87(10):742-5. DOI: 10.1093/jnci/87.10.742. View

19.

Murty V, Bosl G, Houldsworth J, Meyers M, Mukherjee A, Reuter V . Allelic loss and somatic differentiation in human male germ cell tumors. Oncogene. 1994; 9(8):2245-51. View

20.

Wieland I, Bohm M, Arden K, Ammermuller T, Bogatz S, Viars C . Allelic deletion mapping on chromosome 5 in human carcinomas. Oncogene. 1996; 12(1):97-102. View